Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ).
Lumos Diagnostics is hosting an investor and shareholder webinar titled “Reducing Diagnostic Uncertainty” to showcase how its FebriDx rapid diagnostic test supports evidence-based antibiotic stewardship in outpatient and urgent care settings, particularly during the busy cold and flu season. The session will feature real-world insights from WellStreet Urgent Care, where FebriDx has been integrated into high-volume workflows to improve diagnostic clarity, strengthen stewardship practices, and enhance clinical efficiency, underlining the test’s growing clinical adoption and highlighting Lumos’ positioning in the point-of-care diagnostics market; a recording will be available to all registered participants after the event.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd is a Melbourne-based specialist in rapid, point-of-care diagnostic technologies that help healthcare professionals more accurately diagnose and manage medical conditions. The company provides customized assay development and manufacturing services for point-of-care tests, proprietary digital reader platforms, and develops, manufactures, and commercializes its own Lumos-branded tests targeting infectious and inflammatory diseases.
Average Trading Volume: 4,520,074
Technical Sentiment Signal: Buy
Current Market Cap: A$232.2M
Find detailed analytics on LDX stock on TipRanks’ Stock Analysis page.